Form 144 - Report of proposed sale of securities:
SEC Accession No. 0001950047-24-007857
Filing Date
2024-10-23
Accepted
2024-10-23 16:34:24
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html 144  
1 primary_doc.xml 144 4987
  Complete submission text file 0001950047-24-007857.txt   6633
Mailing Address 3 TIMES SQUARE, 12TH FLOOR NEW YORK NY 10036
Business Address
ADAMIS ANTHONY P (Reporting) CIK: 0001277479 (see all company filings)

Type: 144

Mailing Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472
Business Address 480 PLEASANT STREET SUITE B300 WATERTOWN MA 02472 617-926-5000
EyePoint Pharmaceuticals, Inc. (Subject) CIK: 0001314102 (see all company filings)

EIN.: 262774444 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 144 | Act: 33 | File No.: 000-51122 | Film No.: 241389581
SIC: 3826 Laboratory Analytical Instruments
(CF Office: 08 Industrial Applications and Services)